Answers are grounded in this paper and cite their sources.
Background. In 2000, Lalli et al. (Mol Cell Biol 20:4910–4921) reported that the orphannuclear receptor DAX-1 (NR0B1) binds RNA directly, co-purifies with poly(A)+ RNA afterUV crosslinking, and associates with polyribosomes in adrenocortical and Leydig cells.The author of the present study is a co-author of that report. Proteome-wide RNA-bindingprotein (RBP) datasets published since then allow this claim to be re-examinedindependently. Methods. I queried the RBP2GO 2.0 database and re-analysed five public mass-spectrometry datasets: nuclear RBR-ID in mouse embryonic stem cells (mESCs; He et al.2016), mESC oligo(dT) interactome capture (Kwon et al. 2013), RNA interactome captureof mouse male germ cells (Li et al. 2024; PRIDE PXD043074), a deep mESC whole-cellproteome (PRIDE PXD016729) and the mESC ribosome interactome (Simsek et al. 2017).Each dataset was judged by the significance criteria defined in its original publication. Results. NR0B1 was listed in 3 of 62 human RBP2GO datasets, none of them experimental.Dax1 was quantified in all 30 mESC whole-proteome samples (8 unique peptides, 33.1%coverage). In mESC nuclei, 19 Dax1 peptides spanning both the N-terminal repeats and theligand-binding-like domain were quantified by RBR-ID; none met the primary (log2 foldchange < 0, Student's t-test p < 0.05) or extended (p < 0.1) criterion. In the mESC ribo-interactome, Dax1 gave 2 spectra in 1 of 6 bait replicates (SAINT 0.233, FDR 0.247), belowthe published cut-off (SAINT ≥ 0.56, FDR ≤ 0.08, ≥ 4-fold enrichment). Dax1 was notidentified in either oligo(dT) capture dataset, but neither were other pluripotencytranscription factors that are readily detected in the whole-cell proteome. Conclusions. Public proteome-wide data from mESCs do not support RNA binding orribosome association of Dax1, although Dax1 is abundant enough to be quantified. Nocomparable data yet exist for steroidogenic cells, the cell types studied in 2000, so theoriginal claim remains untested there.
No takes yet. Share an insight, caveat, or question.
Kenji Ohe (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: